Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population

2007 ◽  
Vol 2007 ◽  
pp. 59-61
Author(s):  
L.P. Shulman
Keyword(s):  
Down Syndrome ◽  
Ultrasound Examination ◽  
First Trimester ◽  
Second Trimester ◽  
Unselected Population

Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination in an unselected population

2006 ◽  
Vol 195 (5) ◽  
pp. 1379-1387 ◽  
Author(s):  
Patrick Rozenberg ◽  
Laurence Bussières ◽  
Sylvie Chevret ◽  
Jean Pierre Bernard ◽  
Lydia Malagrida ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Ultrasound Examination ◽  
First Trimester ◽  
Second Trimester ◽  
Unselected Population

scholarly journals OC38.01: Screening for Down syndrome using first-trimester combined screening followed by second-trimester ultrasound examination: evaluation of the compliance

2005 ◽  
Vol 26 (4) ◽  
pp. 374-374
Author(s):  
Y. Ville ◽  
P. Rozenberg ◽  
L. Bussières ◽  
J. P. Bernard
Keyword(s):  
Down Syndrome ◽  
Ultrasound Examination ◽  
First Trimester ◽  
Second Trimester

scholarly journals OC38.02: Screening for Down syndrome with a two-step approach using first-trimester combined screening followed by second-trimester ultrasound examination: an interventional study

2005 ◽  
Vol 26 (4) ◽  
pp. 374-374
Author(s):  
Y. Ville ◽  
P. Rozenberg ◽  
L. Bussières ◽  
S. Chevret ◽  
J. P. Bernard
Keyword(s):  
Down Syndrome ◽  
Ultrasound Examination ◽  
First Trimester ◽  
Second Trimester ◽  
Interventional Study

scholarly journals P01.02: Screening for Down syndrome using first-trimester combined screening followed by second-trimester detailed ultrasound examination: an economic evaluation

2005 ◽  
Vol 26 (4) ◽  
pp. 376-376
Author(s):  
Y. Ville ◽  
P. Rozenberg ◽  
I. Durand-Zaleski ◽  
L. Bussières
Keyword(s):  
Down Syndrome ◽  
Economic Evaluation ◽  
Ultrasound Examination ◽  
First Trimester ◽  
Second Trimester

Four Years' Experience With an Interlaboratory Comparison Program Involving First-Trimester Markers of Down Syndrome

2010 ◽  
Vol 134 (11) ◽  
pp. 1685-1691
Author(s):  
Glenn E. Palomaki ◽  
George J. Knight ◽  
Geralyn Lambert-Messerlian ◽  
Jacob A. Canick ◽  
James E. Haddow
Keyword(s):  
Down Syndrome ◽  
Chorionic Gonadotropin ◽  
Plasma Protein ◽  
Human Chorionic Gonadotropin ◽  
Interlaboratory Comparison ◽  
Protein A ◽  
First Trimester ◽  
Nuchal Translucency ◽  
Second Trimester ◽  
Coefficients Of Variation

Abstract Context.—We initiated a voluntary, self-funded interlaboratory comparison program in the fall of 2005 because no proficiency testing program was available to laboratories in North America offering first-trimester, combined serum and ultrasound, Down syndrome screening. Objectives.—To evaluate the first 4 years of the interlaboratory comparison program against stated goals, to identify areas of concern, and to create new initiatives as indicated. Design.—Five serum samples are distributed 3 times a year to be tested for pregnancy-associated plasma protein A, human chorionic gonadotropin or its β subunit, and dimeric inhibin-A; participants convert these results into multiples of the median. Patient histories include nuchal translucency information that enables the calculation of the risk of Down syndrome. Also included are educational components linked to interlaboratory comparison program results. Assessment of integrated (first- and second-trimester markers) risks is accomplished by having participants combine interlaboratory comparison program results with their results from a second-trimester proficiency testing program administered by the College of American Pathologists. Results.—The precision profile for pregnancy-associated plasma protein A shows decreasing coefficients of variation with increasing pregnancy-associated plasma protein A concentrations and multiples of the median (25% to 11% and 30% to 15%, respectively). In contrast, coefficients of variation are a relatively constant 12% throughout the entire range of human chorionic gonadotropin results. On a logarithmic scale, the median coefficient of variation of the risk of Down syndrome is 9%. Conclusions.—Participants in the interlaboratory comparison program reliably measure analytes, compute multiples of the median, and calculate consistent Down syndrome risks. Assays for the measurement of pregnancy-associated plasma protein A are not standardized and are less precise than those for human chorionic gonadotropin. Participants calculate reliable median equations given sonographer-specific sets of paired crown-rump length and nuchal translucency measurements.

scholarly journals The Effect of Down Syndrome Biochemical Markers on Predicting Severity of Preeclampsia

2020 ◽  
Author(s):  
AYSE OZBAN
Keyword(s):  
Down Syndrome ◽  
Pregnant Women ◽  
Biochemical Markers ◽  
First Trimester ◽  
Maternal Serum ◽  
Screening Tests ◽  
Second Trimester ◽  
Study Results ◽  
Second Trimester Screening ◽  
Trimester Screening

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.

Combined first-trimester versus second-trimester serum screening for Down syndrome: A cost analysis

2003 ◽  
Vol 188 (3) ◽  
pp. 745-751 ◽  
Author(s):  
William Cusick ◽  
Philip Buchanan ◽  
Terrence W. Hallahan ◽  
David A Krantz ◽  
John W. Larsen ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Cost Analysis ◽  
First Trimester ◽  
Second Trimester ◽  
Serum Screening
Sign in / Sign up

Export Citation Format

Share Document